Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 212-224

  Grabowska, Agnieszka K ^a   Kaufmann, Andreas M ^b   Riemer, Angelika B ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD4+ T cell epitope; CD4+ T cell immunity; cervical cancer; human papillomavirus; tumor immunotherapy

Indexed keywords

EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E2 156-70; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E2 27-42; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E2 51-65; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E2 59-73; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E2 76-90; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E5 33-48; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E6 129-143; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E6 16-30; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E6 42-56; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E6 54-68; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E6 74-88; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E6 92-106; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 12-26; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 63-77; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 64-78; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 71-85; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 73-87; HUMAN PAPILLOMAVIRUS TYPE 16 PROTEIN E7 76-90; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WART VIRUS VACCINE; CANCER VACCINE; PEPTIDE FRAGMENT; VIRUS PROTEIN;

ALLELE; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG IDENTIFICATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINE PRODUCTION; AMINO ACID SEQUENCE; CELL CULTURE; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHEMISTRY; IMMUNOLOGY; MOLECULAR GENETICS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY;

AMINO ACID SEQUENCE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CERVICAL INTRAEPITHELIAL NEOPLASIA; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRUS INFECTIONS; PEPTIDE FRAGMENTS; TH1 CELLS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL PROTEINS;

EID: 84925284924     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28968     Document Type: Article

References (48)

1. zur Hausen H,. Papillomaviruses in human cancer. Appl Pathol 1987; 5: 19-24.
2. Bosch FX, Lorincz A, Munoz N, et al., The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
3. Gillison ML, Alemany L, Snijders PJ, et al., Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-54.
4. Baseman JG, Koutsky LA,. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 (Suppl 1): S16-24.
5. Schiffman M, Castle PE, Jeronimo J, et al., Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
6. Woodman CB, Collins SI, Young LS,. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11-22.
7. Rodriguez AC, Schiffman M, Herrero R, et al., Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102: 315-24.
8. Evander M, Edlund K, Gustafsson A, et al., Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995; 171: 1026-30.
9. Koutsky L,. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 3-8.
10. Stanley MA,. Immunobiology of papillomavirus infections. J Reprod Immunol 2001; 52: 45-59.
11. Welters MJ, de Jong A, van den Eeden SJ, et al., Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63: 636-41.
12. Nakagawa M, Stites DP, Patel S, et al., Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000; 182: 595-8.
13. van der Burg SH, de Jong A, Welters MJ, et al., The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 2002; 89: 275-84.
14. Ressing ME, van Driel WJ, Brandt RM, et al., Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000; 23: 255-66.
15. Kaufmann AM, Stern PL, Rankin EM, et al., Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002; 8: 3676-85.
16. Garcia F, Petry KU, Muderspach L, et al., ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103: 317-26.
17. Kenter GG, Welters MJ, Valentijn AR, et al., Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
18. Bellanger S, Tan CL, Xue YZ, et al., Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. Am J Cancer Res 2011; 1: 373-89.
19. Xue Y, Lim D, Zhi L, et al., Loss of HPV16 E2 protein expression without disruption of the E2 ORF correlates with carcinogenic progression. Open Virol J 2012; 6: 163-72.
20. Maufort JP, Shai A, Pitot HC, et al., A role for HPV16 E5 in cervical carcinogenesis. Cancer Res 2010; 70: 2924-31.
21. Ganguly N,. Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value. Cell Oncol (Dordr) 2012; 35: 67-76.
22. zur Hausen H,. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 690-8.
23. Tan S, de Vries EG, van der Zee AG, et al., Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 2012; 12: 170-84.
24. Wiesel M, Oxenius A,. From crucial to negligible: functional CD8(+) T-cell responses and their dependence on CD4(+) T-cell help. Eur J Immunol 2012; 42: 1080-8.
25. Williams MA, Holmes BJ, Sun JC, et al., Developing and maintaining protective CD8+ memory T cells. Immunol Rev 2006; 211: 146-53.
26. Shafer-Weaver KA, Watkins SK, Anderson MJ, et al., Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 2009; 69: 6256-64.
27. Bos R, Sherman LA,. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70: 8368-77.
28. van de Berg PJ, van Leeuwen EM, ten Berge IJ, et al., Cytotoxic human CD4(+) T cells. Curr Opin Immunol 2008; 20: 339-43.
29. Brown DM,. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol 2010; 262: 89-95.
30. Grabowska AK, Riemer AB,. The invisible enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J 2012; 6: 249-56.
31. Coleman N, Stanley MA,. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer 1994; 56: 314-9.
32. Zhou JH, Ye F, Chen HZ, Zhou CY, et al., Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci 2006; 78: 2643-9.
33. Bennett SR, Carbone FR, Karamalis F, et al., Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997; 186: 65-70.
34. Wang X, Santin AD, Bellone S, et al., A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunol Immunother 2009; 58: 301-8.
35. Welters MJ, van der Logt P, van den Eeden SJ, et al., Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006; 118: 950-6.
36. Peng S, Trimble C, Wu L, et al., HLA-DQB102-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 2007; 13: 2479-87.
37. van der Burg SH, Ressing ME, Kwappenberg KM, et al., Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001; 91: 612-8.
38. Gallagher KM, Man S,. Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol 2007; 88: 1470-8.
39. Rammensee H, Bachmann J, Emmerich NP, et al., SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-9.
40. Nielsen M, Justesen S, Lund O, et al., NetMHCIIpan-2.0-improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 2010; 6: 9.
41. Nielsen M, Lund O,. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009; 10: 296.
42. de Jong A, van der Burg SH, Kwappenberg KM, et al., Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 472-9.
43. Scott M, Stites DP, Moscicki AB,. Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 1999; 6: 751-5.
44. Bais AG, Beckmann I, Ewing PC, et al., Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls. Mediators Inflamm 2007; 2007: 24147.
45. van der Burg SH, Piersma SJ, de Jong A, et al., Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007; 104: 12087-92.
46. Kim KH, Greenfield WW, Cannon MJ, et al., CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother 2012; 61: 63-70.
47. Visser J, Nijman HW, Hoogenboom BN, et al., Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 2007; 150: 199-209.
48. Riemer AB, Keskin DB, Zhang G, et al., A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem 2010; 285: 29608-22.